TABLE 1.
Demographic, clinical, and baseline laboratory variables for 24 patients treated with AmBa
| Variable | Value (n = 24) |
|---|---|
| Age (yr) | 48.4 ± 16.4 |
| No. of patients with the following characteristic/total no. of patients tested (%): | |
| Gender | |
| Male | 19/24 (79.0) |
| Female | 5/24 (21.0) |
| Place of residence | |
| Salvador, Brazil (capital of Bahia) | 3/24 (12.5) |
| Rural areas | 21/24 (87.5) |
| Reason for AmB treatment | |
| Leishmaniasisb | 22/24 (91.7) |
| Histoplasmosis | 1/24 (4.17) |
| Paracoccidioidomycosis | 1/24 (4.17) |
| Significant comorbidities | |
| HIV infection | 3/24 (12.5) |
| Systemic lupus erythematosus | 1/24 (4.17) |
| Hemophagocytic syndrome | 1/24 (4.17) |
| Cirrhosis | 1/24 (4.17) |
| AmB formulation | |
| Deoxycholate | 12/24 (50.0) |
| Liposomal | 12/24 (50.0) |
| Length of hospital stay (days) | 36.2 ± 15.4 |
| Baseline serum laboratory values | |
| Serum creatinine concn (mg/dl) | 0.8 ± 0.2 |
| Serum potassium concn (meq/liter) | 4.3 ± 0.6 |
| Serum magnesium concn (mg/dl) | 2.0 ± 0.3 |
| Serum bicarbonate concn (meq/liter) | 28.0 ± 4.8 |
| Baseline urine creatinine concn (mg/dl) | 102.2 ± 69.2 |
| No. of patients with the following baseline UrNGAL concn stratum/total no. tested (%): | |
| 0.01–1.00 ng/ml | 18/24 (75.0) |
| 1.00–2.00 ng/ml | 3/24 (12.5) |
| ≥2.00 ng/ml | 3/24 (12.5) |
| Baseline UrNGAL concn | |
| UrNGAL concn (ng/ml) | 1.2 ± 2.9 |
| Log UrNGAL concn (ng/ml) | −1.2 ± 1.7 |
| UrNGAL concn (μg/g creatinine) | 3.1 ± 11.0 |
| Log UrNGAL concn (μg/g creatinine) | −1.1 ± 1.9 |
a
Continuous data are presented as means ± standard deviations. AmB, amphotericin B; UrNGAL, urine neutrophil gelatinase-associated lipocalin.
b
Of the 22 cases of leishmaniasis, 5 were visceral (kala-azar) and 17 were tegumentary (localized cutaneous leishmaniasis, n = 2; disseminated cutaneous leishmaniasis, n = 6; mucosal leishmaniasis, n = 3; disseminated cutaneous leishmaniasis with mucosal involvement, n = 6).